X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2025)
X4 Pharmaceuticals (XFOR) posted EBITDA Margin of 922.86% for Q4 2025, up 40.79% on a QoQ basis from 1558.58% in Q3 2025, and up 156773.0% year-over-year from N/an in Q4 2024.
X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals' EBITDA Margin history runs 4 years deep, the most recent figure standing at 922.86% for Q4 2025.
- Quarterly EBITDA Margin rose 156773.0% year-over-year to 922.86% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 247.44% (up 117614.0% YoY) and the FY2025 annual result came in at 247.44%, up 117614.0% from the prior year.
- EBITDA Margin was 922.86% for Q4 2025 at X4 Pharmaceuticals, up from 1558.58% in the prior quarter.
- Across five years, EBITDA Margin topped out at 12629.31% in Q2 2024 and bottomed at 6160.71% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -922.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -922.86% |
| Sep 30, 2025 | -1,558.58% |
| Jun 30, 2025 | -1,329.55% |
| Mar 31, 2025 | -32.78% |
| Dec 31, 2024 | -2,490.59% |
| Sep 30, 2024 | -6,160.71% |
| Jun 30, 2024 | 12,629.31% |
| Mar 31, 2020 | -352.70% |
| Dec 31, 2018 | -230.11% |